Osimertinib as 1st Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT05127382

HE219

Ages > 18
All Genders

Study Summary

The present study will evaluate the use of osimertinib as 1st line therapy for patients with advanced EGFR positive non-small cell lung cancer who are treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology.

Eligibility Criteria

Inclusion

Inclusion Criteria:

men or women of 18 years or older that live in Greece
histologically or cytologically confirmed, advanced EGFR positive non-small cell lungcancer
untreated patients for advanced NSCLC
patients who are expected to receive osimertinib regardless of their enrollment in thestudy
signed written informed consent

Exclusion

Exclusion Criteria:

patients with cancer other than NSCLC that require treatment
pretreated patients for NSCLC
patients that receive or are expected to receive or have received an investigationaldrug/product/intervention

Study Design

February 01, 2020

January 31, 2025

Study Description

This will be an observational, multicentric, retrospective/ prospective analysis of patients with advanced EGFR positive non-small cell lung cancer that receive osimertinib as 1st line therapy. The patient data will be collected at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology during scheduled patient clinical visits, from February 2020 for a total period of three years. The biological material obtained from the patients of this analysis will be possibly used in a future translational study as an exploratory analysis.

Connect with a study center

Hellenic Cooperative Oncology Group
Athens, 11526
Greece
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.